Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Vasovist
Gadofosveset trisodium is a gadolinium-based contrast agent (GBCA) used in magnetic resonance imaging (MRI) to enhance the visibility of blood vessels and tissues. It is classified as a blood pool contrast agent due to its strong binding to albumin, which prolongs its vascular half-life and allows for improved visualization of the vascular system. This property makes it particularly useful in magnetic resonance angiography (MRA).
Used in magnetic resonance angiography (MRA) to enhance the visualization of blood vessels.
Gadolinium-based contrast agents (GBCAs) increase the risk of nephrogenic systemic fibrosis (NSF) in patients with acute kidney injury or chronic, severe kidney disease (glomerular filtration rate < 30 mL/min/1.73m2). Screen all patients for renal function by obtaining a history and/or laboratory tests. Do not administer GBCAs to patients with acute kidney injury or chronic, severe kidney disease unless the diagnostic information is essential and not available through other means. After GBCA administration, monitor all patients for signs and symptoms of NSF.
Outcome:
Increased risk of nephrogenic systemic fibrosis (NSF)
Mechanism:
Reduced renal clearance of gadofosveset
Outcome:
Increased risk of QT prolongation and torsades de pointes
Mechanism:
Additive effects on cardiac repolarization
Outcome:
Reduced efficacy of gadofosveset
Mechanism:
Binding of gadofosveset to iron
Most likely new formulation: None predicted (Low Confidence)
Based on current usage trends and safety profile, there is a low probability of regulatory changes in the next 5 years.
MRI Contrast Agent, Gadolinium-based Contrast Agent
Gadolinium Chelate